Medicenna Therapeutics Corp (MDNA) Price & Analysis

Q: What was Medicenna Therapeutics Corp’s price range in the past 12 months?

Medicenna Therapeutics Corp lowest stock price was C$0.78 and its highest was C$2.16 in the past 12 months.

Q: What is Medicenna Therapeutics Corp’s market cap?

Medicenna Therapeutics Corp’s market cap is C$102.40M.

Q: When is Medicenna Therapeutics Corp’s upcoming earnings report date?

Medicenna Therapeutics Corp’s upcoming earnings report date is Feb 12, 2026 which is in 70 days.

Q: How were Medicenna Therapeutics Corp’s earnings last quarter?

Medicenna Therapeutics Corp released its earnings results on Nov 13, 2025. The company reported -C$0.06 earnings per share for the quarter, missing the consensus estimate of -C$0.053 by -C$0.007.

Q: Is Medicenna Therapeutics Corp overvalued?

According to Wall Street analysts Medicenna Therapeutics Corp’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Q: Does Medicenna Therapeutics Corp pay dividends?

Medicenna Therapeutics Corp does not currently pay dividends.

Q: What is Medicenna Therapeutics Corp’s EPS estimate?

Medicenna Therapeutics Corp’s EPS estimate is -0.07.

Q: How many shares outstanding does Medicenna Therapeutics Corp have?

Medicenna Therapeutics Corp has 68,726,980 shares outstanding.

Q: What happened to Medicenna Therapeutics Corp’s price movement after its last earnings report?

Medicenna Therapeutics Corp reported an EPS of -C$0.06 in its last earnings report, missing expectations of -C$0.053. Following the earnings report the stock price went down -0.725%.

Q: Which hedge fund is a major shareholder of Medicenna Therapeutics Corp?

Currently, no hedge funds are holding shares in TSE:MDNA

Compare

227 Followers

MDNA Stock Chart & Stats

C$1.53

-C$0.01(-0.67%)

At close: Jan 08 4:00 PM EST

C$1.53

-C$0.01(-0.67%)

Day’s Range― - ―

52-Week RangeC$0.78 - C$2.16

Previous CloseN/A

Volume26.49K

Average Volume (3M)30.62K

Market Cap

C$102.40M

Enterprise ValueC$49.85M

Total Cash (Recent Filing)C$20.46M

Total Debt (Recent Filing)C$162.00K

Price to Earnings (P/E)―

Beta1.84

Next Earnings

Feb 12, 2026

EPS Estimate

-0.07

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.06

Shares Outstanding68,726,980

10 Day Avg. Volume37,956

30 Day Avg. Volume30,624

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)24.28

Price to Sales (P/S)0.00

P/FCF Ratio-7.75

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

C$6.19

Price Target Upside304.58% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Growth OpportunitiesPharma interest in PD1 bispecifics is increasing, indicating potential growth opportunities in this area for companies like Medicenna Therapeutics.

Market InterestRecent high-value deals in the anti-PD1 bispecifics sector suggest strong market interest and investment in similar therapeutic approaches.

Therapeutic PotentialThe Takeda and Innovent agreement highlights the potential of PD-1/IL-2 bispecifics, which could benefit companies involved in similar research.

Bears Say

Medicenna Therapeutics Corp News

Medicenna Therapeutics Reports Q2 2026 Results and Announces Key Developments in Superkine Programs

Medicenna Therapeutics Corp ( ($TSE:MDNA) ) has issued an update. Medicenna Therapeutics Corp announced its second quarter fiscal...

21d ago

Medicenna Therapeutics (MDNA) Q2 Earnings Cheat Sheet

Medicenna Therapeutics (MDNA) is scheduled to report 2nd quarter earnings on 11/14/2025. Regarding Q2 estimates, Wall Street analysts...

22d ago

Medicenna Partners with Fondazione Melanoma Onlus for Pioneering Melanoma Trial

The latest update is out from Medicenna Therapeutics Corp ( ($TSE:MDNA) ). Medicenna Therapeutics Corp has announced a...

28d ago

Medicenna’s MDNA11 Study: A Potential Game-Changer in Cancer Treatment?

Medicenna Therapeutics (($TSE:MDNA)) announced an update on their ongoing clinical study. Medicenna Therapeutics is conducting a Phase 1/2...

1M ago

MDNA

Medicenna to Present Updated MDNA11 Data at ESMO Congress 2025

Medicenna Therapeutics Corp ( ($TSE:MDNA) ) has provided an announcement. Medicenna Therapeutics Corp announced that updated clinical data...

1M ago

Medicenna Therapeutics Corp: Positioned for Growth in the PD-1 Bispecific Antibody Market

Analyst David Martin PhD of Bloom Burton maintained a Buy rating on Medicenna Therapeutics Corp, retaining the price...

1M ago

Medicenna Therapeutics to Showcase Innovations at Upcoming Conferences

An update from Medicenna Therapeutics Corp ( ($TSE:MDNA) ) is now available. Medicenna Therapeutics Corp announced its participation...

1M ago

Medicenna Therapeutics initiated with a Buy at Lucid Capital

Lucid Capital initiated coverage of Medicenna Therapeutics (MDNAF) with a Buy rating and C$4 price target Published first...

2M ago

Promising Developments in Medicenna Therapeutics Corp’s ABILITY-1 Trial Justify Buy Rating

In a report released on September 30, David Martin PhD from Bloom Burton maintained a Buy rating on...

2M ago

Medicenna to Engage Investors at ROTH Healthcare Conference

The latest update is out from Medicenna Therapeutics Corp ( ($TSE:MDNA) ). Medicenna Therapeutics announced that its President...

2M ago

Medicenna Therapeutics Announces Shareholder Meeting Results and Leadership Updates

An update from Medicenna Therapeutics Corp ( ($TSE:MDNA) ) is now available. Medicenna Therapeutics Corp announced the results...

2M ago

Medicenna Therapeutics CFO Jeff Caravella, CBO Brent Meadows depart

The Company announced the departure of Jeff Caravella as Chief Financial Officer, and Brent Meadows as Chief Business...

2y ago

MDNA

Medicenna Therapeutics reduces size of management team, U.S. presence

In connection with the Nasdaq delisting and in effort to further preserve capital, the Board decided to reduce...

2y ago

MDNA

Medicenna Therapeutics to seek listing of common shares on OTC Markets

After careful consideration, the Board of Directors of Medicenna determined that it is in the overall best interests...

2y ago

MDNA

MDNA FAQ

What was Medicenna Therapeutics Corp’s price range in the past 12 months?

Medicenna Therapeutics Corp lowest stock price was C$0.78 and its highest was C$2.16 in the past 12 months.

What is Medicenna Therapeutics Corp’s market cap?

Medicenna Therapeutics Corp’s market cap is C$102.40M.

When is Medicenna Therapeutics Corp’s upcoming earnings report date?

Medicenna Therapeutics Corp’s upcoming earnings report date is Feb 12, 2026 which is in 70 days.

How were Medicenna Therapeutics Corp’s earnings last quarter?

Medicenna Therapeutics Corp released its earnings results on Nov 13, 2025. The company reported -C$0.06 earnings per share for the quarter, missing the consensus estimate of -C$0.053 by -C$0.007.

Is Medicenna Therapeutics Corp overvalued?

According to Wall Street analysts Medicenna Therapeutics Corp’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Medicenna Therapeutics Corp pay dividends?

Medicenna Therapeutics Corp does not currently pay dividends.

What is Medicenna Therapeutics Corp’s EPS estimate?

Medicenna Therapeutics Corp’s EPS estimate is -0.07.

How many shares outstanding does Medicenna Therapeutics Corp have?

Medicenna Therapeutics Corp has 68,726,980 shares outstanding.

What happened to Medicenna Therapeutics Corp’s price movement after its last earnings report?

Medicenna Therapeutics Corp reported an EPS of -C$0.06 in its last earnings report, missing expectations of -C$0.053. Following the earnings report the stock price went down -0.725%.

Which hedge fund is a major shareholder of Medicenna Therapeutics Corp?

Currently, no hedge funds are holding shares in TSE:MDNA

Medicenna Therapeutics Corp Stock Smart Score

Neutral

Analyst Consensus

Moderate Buy

Average Price Target:
C$6.19 (304.58% Upside)

Technicals

Fundamentals

Return on Equity

-91.21%

Trailing 12-Months

Asset Growth

-40.12%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Medicenna Therapeutics Corp

Medicenna Therapeutics Corp (MDNA) is a clinical-stage immunotherapy company focused on the development and commercialization of highly selective engineered cytokines for cancer treatment. Operating within the biotechnology sector, Medicenna's core products include a pipeline of Superkines and Empowered Cytokines designed to enhance the immune system's ability to fight cancer. The company's proprietary approach aims to develop therapies that can selectively stimulate or inhibit specific receptor pathways associated with various cancers.

Medicenna Therapeutics Corp (MDNA) Earnings & Revenues

Historic Earnings Reports

MDNA Stock 12 Month Forecast

Average Price Target

C$6.19

▲(304.58% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"C$4","9":"C$9","-1":"-C$1","1.5":"C$1.5","6.5":"C$6.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8.37978294,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$8.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$6.19</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.5,4,6.5,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.96,1.5307525338461538,2.1015050676923077,2.672257601538462,3.2430101353846155,3.813762669230769,4.384515203076923,4.955267736923077,5.526020270769231,6.096772804615385,6.667525338461538,7.238277872307693,7.8090304061538465,{"y":8.37978294,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.96,1.3623076923076924,1.7646153846153847,2.166923076923077,2.5692307692307694,2.971538461538462,3.373846153846154,3.7761538461538464,4.178461538461539,4.580769230769231,4.983076923076924,5.385384615384616,5.787692307692308,{"y":6.19,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.96,1.1938461538461538,1.4276923076923076,1.6615384615384614,1.8953846153846152,2.1292307692307695,2.363076923076923,2.596923076923077,2.8307692307692305,3.0646153846153847,3.2984615384615386,3.5323076923076924,3.766153846153846,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.22,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.42,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.81,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.28,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.51,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.62,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.65,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.32,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.04,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.97,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.22,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.06,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.96,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >